SuperworthBecton, Dickinson and BDX
- Market cap
- $54.2B
- PE
- 60.1×
- 10y median 37.5×
- Forward PE
- 15.1×
- 10y median 16.2×
- Price to sales
- 2.6×
- EV/EBIT
- 22.1×
- Revenue, 12 months
- $20.8B
- +5% on a year ago
- Net margin
- 4.5%
- Free cash flow yield
- 5.0%
Becton, Dickinson and trades at 60.1× trailing earnings, pricier than 81% of the last ten years. Revenue was $20.8B over the last twelve months, up 5% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.1B+7% | $4.7B+3% | $5B+5% | $5B+2% | $5.4B+7% | $5.2B+10% | $4.5B−11% | $4.7B−5% | $5.9B+8% | $5.3B+2% | $4.7B+5% | $5B+5% | |
| Cost of revenue | $3.4B+26% | $2.7B+9% | $2.7B+6% | $2.7B−3% | $3B−13% | $2.9B+10% | $2.6B−5% | $2.5B−7% | $3.1B+5% | $2.8B−3% | $2.6B−2% | $2.7B+7% |
| Gross profit | $1.7B−18% | $2B−5% | $2.3B+3% | $2.3B+10% | $2.5B+46% | $2.2B+10% | $1.9B−19% | $2.2B−3% | $2.8B+13% | $2.4B+8% | $2.2B+16% | $2.3B+4% |
| R&D | $281M−6% | $290M−7% | $299M−11% | $299M−2% | $302M+8% | $343M+18% | $232M−22% | $230M−23% | $322M+7% | $306M−11% | $249M+7% | $258M+12% |
| SG&A | $1.1B−4% | $1.2B+2% | $1.2B−1% | $1.2B+1% | $1.3B+10% | $1.3B+9% | $1.1B−6% | $1.2B−3% | $1.4B+9% | $1.4B+6% | $1.2B+9% | $1.3B+8% |
| $349M−29% | $439M−25% | $734M+17% | $602M+10% | $622M+78% | $453M+3% | $383M−48% | $739M+23% | $697M+12% | $552M+22% | $93M−76% | $663M−10% | |
| Interest expense | $113M+9% | $111M+9% | $125M+6% | $137M+15% | $155M+37% | $155M+40% | $150M+20% | $152M+11% | $155M+0% | $153M−1% | $149M−1% | $132M−13% |
| Pre-tax income | $181M−43% | $359M−25% | $633M+20% | $500M+6% | $514M+184% | $306M−15% | $201M−68% | $569M+14% | $510M−1% | $393M+28% | $39M−81% | $554M−3% |
| $28M−15% | $77M | $96M+41% | $13M−80% | $114M+307% | $3M−96% | $43M−55% | $118M+808% | $17M−85% | $11M+267% | $76M+77% | $102M−14% | |
| Net income | $108M−63% | $281M−45% | $537M+17% | $487M+20% | $400M+270% | $303M+8% | $308M−43% | $574M+18% | $493M+23% | $382M+26% | −$311M | $377M−34% |
| $0.37−60% | $0.96−44% | $1.85+21% | $1.68+24% | $1.37+270% | $1.04+8% | $1.07−42% | $2.00+19% | $1.71+25% | $1.34+29% | −$1.11 | $1.37−32% | |
| 294.4M+3% | 291.4M+2% | 290.3M+2% | 290.3M+1% | 291.5M−1% | 290.4M−0% | 287.7M−1% | 287.2M−1% | 288M−1% | 285.8M−2% | 280.6M−3% | 275.2M−4% |
Gross profit: 73 periods, Q3 FY08 to Q3 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY08 and Q4 FY09: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q3 FY08 to Q2 FY09: not printed by the filing, worked out from its own lines. 16 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $5.1B | $5.1B to $5.2B | $4.07 | $4.04 to $4.11 | 10 |
| Q1 FY27 | $4.6B | $4.4B to $5.2B | $2.71 | $2.65 to $2.79 | 7 |
| Q2 FY27 | $4.8B | $4.7B to $5.1B | $3.02 | $2.91 to $3.29 | 2 |
| Q3 FY27 | $5.1B | $4.9B to $5.4B | $3.38 | $3.26 to $3.68 | 2 |
| Q4 FY27 | $5.2B | $5.1B to $5.6B | $4.06 | $3.92 to $4.43 | 2 |
| Q1 FY28 | $4.7B | $4.6B to $5.1B | $3.04 | $2.93 to $3.31 | 5 |
| Q2 FY28 | $5B | $4.9B to $5.3B | $3.34 | $3.22 to $3.64 | 6 |
| Q3 FY28 | $5.3B | $5.1B to $5.6B | $3.71 | $3.58 to $4.05 | 5 |
Peers
Companies in Medical - Instruments & Supplies nearest Becton, Dickinson and's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BDXBecton, Dickinson and | $54.2B | 60.1× | 37.5× | 15.1× | 2.6× | +5% | 4.5% |
| MDLNMedline | $44.8B | n/m | n/a | 23.2× | n/m | n/m | n/m |
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| ISRGIntuitive Surgical | $159.8B | 54.7× | 69.3× | 37.5× | 13.8× | +20% | 25.5% |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | n/m | 1.7× | −1% | 17.3% |
| PENPenumbra | $12.8B | 79.7× | 197× | n/m | 8.5× | +18% | 10.7% |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | n/m | 2.7× | +5% | 13.5% |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | n/m | 2.7× | +4% | 10.0% |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | n/m | 3.5× | +20% | 17.0% |
| PODDInsulet | $10.3B | 27.9× | 63.0× | n/m | 3.4× | +29% | 12.3% |
| Peer median | $13.7B | 26.9× | 43.3× | 30.4× | 3.5× | +12% | 17.0% |
Investors who own it
Investors we follow who held Becton, Dickinson and at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)0.5% of portfolioadded
More on Becton, Dickinson and
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .